Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 43063-371

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 43063-371). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063371 Label (43063371)

This is a warning for the drug Clopidogrel 75 mg, which is contained in each of the 30 tablets in the package, and it is important to keep it out of the reach of children. The drug is coated, and each tablet contains 75 mg of Clopidogrel Bisulfate USP. The package includes a package insert with directions for dosage and storage, while side effects should be reported to the FDA or a medical doctor. The drug should be taken several times per day, and the lot number is C2205, with an expiration date of 09/2023. The manufacturer is listed as Pharmaceuticals and is based in Oklahoma City.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 01

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 02

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 03

This is a description of a chart that displays the cumulative event rate in percentage for cardiovascular death, myocardial infarction, and stroke for patients taking either a placebo or Topidogrel bisuate in combination with aspirin. The chart shows the data for a follow-up period of 12 months, and other standard therapies were also used as appropriate.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 04

This is a table showing the Hazard Ratio for Patient Baseline Characteristics and On-Study Concomitant Medications/Interventions for the CURE Study. The table includes subgroups based on patient age, gender, race, elevated cardiac enzymes, diabetes, previous MI, and previous stroke. The number of patients in each subgroup is provided along with the number and percentage of patients who received clopidogrel versus placebo. The table also shows the hazard ratio and 95% confidence interval for each subgroup. No further information is given.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 05

The text provides a table showing hazard ratios for different patient baseline characteristics and concomitant medications/interventions for the CURE study. It shows the number of patients in each subgroup, the number and percentage of patients taking Clopidogrel and Placebo, and which treatment was favored. The baseline characteristics include Heparin/LMWH, Aspirin(mg), GPIIb/IlIa Antag, Beta-Blocker, and Ace Inhibitor. The table also presents the overall hazard ratio (with 95% CI).*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 06

The text describes a figure (Figure 4) that shows cumulative event rates for death in the COMMIT study. The figure compares the death rates of two groups: a placebo group (which had 1645 deaths, or 8.1% of participants) and a group that received clopidogrel (which had 1726 deaths, or 7.5% of participants). The figure also displays a proportional risk reduction of 7% before discharge and 5% after discharge (at up to 28 days since randomization) for clopidogrel compared to placebo. All treated patients received aspirin.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 07

This is a statistical comparison of two groups of patients who received either a placebo or clopidogrel while also taking aspirin. The number of patients who experienced an event (not specified) is given for each group, along with the percentage of patients who experienced an event. The proportional risk reduction for the clopidogrel group compared to the placebo group is given as 9% with a p-value of 0.002, indicating that the difference between the two groups is statistically significant.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 08

The text represents a table (Figure 6) that shows the effects of adding Clopidogrel Bisulfate to Aspirin on the primary endpoint of the COMMIT study, across different subgroups based on gender, age, hours since onset, systolic blood pressure, heart rate, and use of fibrinolytic agent. The table presents the number of participants in each subgroup, the percentage of participants given Clopidogrel Bisulfate or a placebo, and the odds ratio for favoring Clopidogrel Bisulfate or Placebo.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 09

This is a table showing the cumulative event rate for fatal or non-fatal vascular events over a period of 24 months of follow-up. The data refers to the medication clopidogrel bisulfate. There are five time points, and the event rate percentage is not specified.*

FDA Label Image

Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 10

This appears to be a chart or table displaying the results of a study on the use of Clopidogrel and Aspirin for patients with qualifying conditions such as Stroke, MI, and PAD. The table includes the number of patients in each group (Clopidogrel and Aspirin), as well as their percentages. The bottom row shows the Hazard Ratio and indicates that Clopidogrel may be the preferred treatment option.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.